Trinity Biotech plc (TRIB)
Market Cap | 16.44M |
Revenue (ttm) | 66.27M |
Net Income (ttm) | -30.82M |
Shares Out | 38.21M |
EPS (ttm) | -1.05 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 293,569 |
Open | 0.380 |
Previous Close | 0.376 |
Day's Range | 0.380 - 0.560 |
52-Week Range | 0.370 - 1.370 |
Beta | 1.45 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Dec 14, 2023 |
About TRIB
Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, ru... [Read more]
Financial Performance
Financial StatementsNews

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares
DUBLIN, Ireland, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical l...

Trinity Biotech Announces Q2 2023 Financial Results
DUBLIN, Ireland, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets...

Trinity Biotech plc to Announce Second Quarter Fiscal Year 2023 Financial Results
DUBLIN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will r...

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement
DUBLIN, Ireland, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical ...

Trinity Biotech Announces That It Has Received 510(k) Clearance From The U.S. Food and Drug Administration for the Premier Resolution System
DUBLIN, Ireland, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Premier Resolution System, an automated analyzer for th...

Trinity Biotech Announces Q1 2023 Financial Results
DUBLIN, Ireland, July 06, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets...

Trinity Biotech plc to Announce First Quarter Fiscal Year 2023 Financial Results
DUBLIN, July 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will re...

Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
DUBLIN, Ireland, May 05, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical la...

Trinity Biotech Announces the Successful Closing of the $30 Million Sale of its Life Sciences Supply Business to Biosynth
DUBLIN, Ireland, April 27, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical ...

Trinity Biotech Announces the $30 Million Sale of its Life Sciences Supply Business to Biosynth
DUBLIN, Ireland, April 20, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical ...

Trinity Biotech Announces Fourth Quarter and Fiscal Year 2022 Financial Results
DUBLIN, Ireland, March 23, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory market...

Trinity Biotech Welcomes TrinScreen HIV's Inclusion In The New Kenyan HIV Testing Algorithm
DUBLIN, Ireland, March 22, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical l...

Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2022 Financial Results
Conference Call Scheduled for March 23, 2023 at 10:00 am EASTERN Conference Call Scheduled for March 23, 2023 at 10:00 am EASTERN

Trinity Biotech Announces Entry Into An Increased Loan Facility to Fund Potential Acquisitions
DUBLIN, Ireland, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical la...

Trinity Biotech Announces Strategic Partnership with imaware™ to Deliver Integrated Diagnostic Testing Solutions to Digital Health Industry
DUBLIN, Ireland, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, t...

Trinity Biotech Announces Q3 2022 Financial Results
DUBLIN, Ireland, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets...

Trinity Biotech plc to Announce Third Quarter Fiscal Year 2022 Financial Results
Conference Call Scheduled for December 15, 2022 at 11:00 am EASTERN Conference Call Scheduled for December 15, 2022 at 11:00 am EASTERN

Trinity Biotech to participate in the Piper Sandler 34th Annual Healthcare Conference
DUBLIN, Ireland, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, is...

Trinity Biotech Announces Quarter 2 2022 Financial Results And Preliminary Q3 2022 Revenue Guidance
DUBLIN, Ireland, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets...

Trinity Biotech plc to Announce Second Quarter Fiscal Year 2022 Financial Results
Conference Call Scheduled for November 3, 2022 at 11:00 am EASTERN Conference Call Scheduled for November 3, 2022 at 11:00 am EASTERN

Trinity Biotech Announces the Appointment of Tom Lindsay to its Board of Directors
DUBLIN, Ireland, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets...

Trinity Biotech Announces The Appointment of Aris Kekedjian As Chairman and CEO
DUBLIN, Ireland, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets...

Trinity Biotech Announces Results of AGM
DUBLIN, Ireland, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory market...

Trinity Biotech Announces Quarter 1 2022 Financial Results
DUBLIN, Ireland, June 30, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets...

Trinity Biotech plc to Announce First Quarter Fiscal Year 2022 Financial Results
Conference Call Scheduled for June 30, 2022 at 11:00 am EASTERN Conference Call Scheduled for June 30, 2022 at 11:00 am EASTERN